RVXCF News Alert Resverlogix Corp (RVXCF) 0.4090 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Resverlogix Corp (RVXCF) 0.4090 $RVXCF

Resverlogix Names Michael Sweeney, M.D., as Senior Vice President of Clinical Development
PR Newswire - Mon Nov 03, 4:05PM CST
Resverlogix Corp. (TSX:RVX) today announced the appointment of Michael T. Sweeney, M.D., as senior vice president of clinical development.
RVX.TO: 0.49 (+0.01)

Resverlogix Corporate Update Conference Call & Webcast Announcement
PR Newswire - Wed Oct 01, 1:00PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 0.49 (+0.01)

Resverlogix Corp. Closes Additional $30 million from Citibank Loan
PR Newswire - Fri Aug 15, 4:00PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 0.49 (+0.01)

Resverlogix Corp. Shareholders Approve Additional $30 million from Citibank Loan
PR Newswire - Wed Aug 13, 4:01PM CDT
TSX Exchange Symbol: RVX
RVX.TO: 0.49 (+0.01)

Restenosis - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fzlqdr/restenosis) has announced the addition of the "Restenosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Restenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restenosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Restenosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Restenosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Shire Plc - Resverlogix Corp. - CytoTools AG - Angelini Group - Viron Therapeutics, Inc. - AIM Therapeutics Inc. - CSPC NBP Pharmaceutical Co.,ltd - XBiotech USA, Inc. For more information visit http://www.researchandmarkets.com/research/fzlqdr/restenosis
SHPG: 209.29 (+0.07)

CounterPath to Present at Needham Growth Conference
Marketwire Canada - Thu Jan 09, 6:57PM CST
CounterPath Corporation (NASDAQ:CPAH)(TSX:CCV), an award-winning provider of desktop and mobile VoIP software products and solutions, announces that Donovan Jones, President and Chief Executive Officer, will present at the 16th Annual Needham Growth Conference. Mr. Jones will outline CounterPath's VoIP software and services, its customer relationships, its IP portfolio and the sector outlook.
CCV.TO: 0.73 (+0.11), CPAH: 0.61 (+0.05), ISIS: 59.49 (+1.88), MRK: 57.46 (+0.25), BMY: 59.15 (-0.01), MNTA: 11.42 (-0.06), NVS: 93.91 (+0.66)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Perigon Builds Its Investment Bench for the Next Leg

Updated Category News Views 129

Perigon is rearranging the engine room before the next growth spurt gets noisy. The firm has named Christopher Broderick Director of Investments and Research, added two trading associates, and put another brick behind the broader operating structure Rafia Hasan has been assembling since taking on the chief operating officer role in August. That may sound like ordinary...

Continue Reading
Teachstone’s Bronze Award Puts Classroom Quality in Focus

Updated Category News Views 36

Small Classroom Moments Finally Get Their Due A child’s hesitant question can disappear in the noise of a busy classroom, which is precisely why Teachstone’s latest recognition deserves more than the usual polite golf clap. The Charlottesville-based Certified B Corporation received a Bronze Anthem Award for its “From Measurement to Momentum” initiative, in the...

Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 75

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
CASEKOO's Montana Story Makes Brand Purpose Personal

Updated Category News Views 45

A blurry Montana kitchen, not a glossy product render, is doing the heavy lifting for CASEKOO this Thanksgiving. That is either a smart bit of brand discipline or a sentimental detour, depending on whether the company can make people feel something without losing sight of why they bought a phone case in the first place. Warmth Takes the Place of Hardware CASEKOO's new...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 100

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
U.S. Employers Signal a Deeper Multilingual Skills Gap

Updated Category News Views 90

A language gap rarely makes the loudest noise in an earnings call, yet it can quietly wreck a sales effort, a hiring plan, or a customer relationship. ACTFL's updated 2026 employer study puts some hard edges around that problem: U.S. businesses say multilingual capability is not a nice cultural accessory. It is increasingly part of operating the business. Demand Has Moved...

Continue Reading
Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 72

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 121

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 88

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading

Top 5 Most Recently Viewed Articles

Specialty1 Partners Drives New Growth Through Partnerships

Updated Category News Views 227

Specialty1 Partners Fuels Growth with Innovative Model Specialty1 Partners (S1P) has emerged as a leader in the specialty dental partnership sector, focusing on aiding Endodontists, Periodontists, and Oral Surgeons in elevating their practices. Their innovative joint venture model is increasingly attracting dental specialists eager to transition from associates to...

Continue Reading
Union Pacific in Talks for Major Norfolk Southern Merger

Updated Category News Views 263

Union Pacific's Ambitious Merger Talks Union Pacific Corp. (NYSE: UNP) is reportedly engaged in preliminary discussions to acquire Norfolk Southern Corp. (NYSE: NSC), marking a prospective mega-merger in the railroad industry. While details are still emerging, the implications of such a merger could significantly reshape the freight transport landscape across the United...

Continue Reading
Great Elm Capital Corp.'s Impressive Second Quarter Performance

Updated Category News Views 147

Overview of Financial Achievements Great Elm Capital Corp. (NASDAQ: GECC) has recently released its financial performance report for the second quarter, demonstrating remarkable growth and a prosperous quarter for the company. This update is essential for investors and stakeholders keen on understanding the company's current financial health and future prospects. Record...

Continue Reading
Scandinavian Tobacco Group Updates on Share Buy-back Activities

Updated Category News Views 211

Scandinavian Tobacco Group A/S launched a significant share buy-back program back in November, worth up to DKK 850 million. The move aimed at adjusting the company's capital structure and meeting obligations tied to its share-based incentive programs. This isn’t just a random act; it’s a strategic ploy in a competitive market that’s meant to bolster their stock...

Continue Reading
Breakthrough Outcomes of Telitacicept in Sjögren's Syndrome Study

Updated Category News Views 220

Exciting Developments in Telitacicept Phase III Trial Results The Phase III clinical trial results for Telitacicept are sparking significant interest, particularly within the realm of Sjögren's Syndrome. This autoimmune condition can severely affect patients' quality of life due to symptoms like dry mouth and dry eyes, among others. Recently, announcements surrounding...

Continue Reading